Alasdair J Coles

List of Publications by Citations

105 papers	13,643 citations	42 h-index	112 g-index
112 ext. papers	15,616 ext. citations	9.1 avg, IF	6.66 L-index

#	Paper	IF	Citations
105	Multiple sclerosis. *Lancet, The*, **2008**, 372, 1502-17	40	3360
104	Multiple sclerosis. *Lancet, The*, **2002**, 359, 1221-31	40	1618
103	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet, The*, **2012**, 380, 1819-28	40	834
102	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet, The*, **2012**, 380, 1829-39	40	827
101	Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. *New England Journal of Medicine*, **2008**, 359, 1786-801	59.2	769
100	Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. *Annals of Neurology*, **1999**, 46, 296-304	9.4	438
99	The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. *Journal of Neurology*, **2006**, 253, 98-108	5.5	401
98	Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. *Lancet, The*, **1999**, 354, 1691-5	40	398
97	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. *European Journal of Immunology*, **2005**, 35, 3332-42	6.1	248
96	Disease-relevant autoantibodies in first episode schizophrenia. *Journal of Neurology*, **2011**, 258, 686-8	5.5	236
95	Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. *Journal of Clinical Investigation*, **2010**, 120, 4220-35	15.9	229
94	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. *Brain*, **1996**, 119 (Pt 1), 225-37	11.2	227
93	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). *Journal of Clinical Investigation*, **2009**, 119, 2052-61	15.9	215
92	B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. *Journal of Clinical Immunology*, **2010**, 30, 99-105	5.7	180
91	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. *Neurology*, **2017**, 89, 1117-1126	6.5	175
90	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA - Journal of the American Medical Association*, **2019**, 321, 175-187	27.4	172
89	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 208-15	5.5	164

88	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 20200-5	11.5	149
87	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 298-304	5.5	148
86	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. *Neurology*, **2017**, 89, 1107-1116	6.5	139
85	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. *Brain*, **2010**, 133, 2232-47	11.2	131
84	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. *Brain*, **2013**, 136, 2888-903	11.2	130
83	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. *Practical Neurology*, **2015**, 15, 273-9	2.4	118
82	Alemtuzumab versus interferon β1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. *Lancet Neurology, The*, **2011**, 10, 338-48	24.1	108
81	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. *Lancet Neurology, The*, **2017**, 16, 271-281	24.1	101
80	Immune competence after alemtuzumab treatment of multiple sclerosis. *Neurology*, **2013**, 81, 872-6	6.5	95
79	Quantifying normal human brain metabolism using hyperpolarized [1-C]pyruvate and magnetic resonance imaging. *NeuroImage*, **2019**, 189, 171-179	7.9	92
78	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. *Blood*, **2011**, 118, 6299-305	2.2	84
77	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 708-13	5.5	81
76	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurology, The*, **2020**, 19, 307-316	24.1	77
75	Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. *Clinical Neurology and Neurosurgery*, **2004**, 106, 270-4	2	76
74	Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. *European Journal of Neuroscience*, **2003**, 18, 2527-37	3.5	64
73	Alemtuzumab therapy for multiple sclerosis. *Neurotherapeutics*, **2013**, 10, 29-33	6.4	58
72	A novel strategy to reduce the immunogenicity of biological therapies. *Journal of Immunology*, **2010**, 185, 763-8	5.3	58
71	Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series. *Schizophrenia Research*, **2014**, 160, 193-5	3.6	53

70	Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. *Lancet, The*, **2021**, 398, 1147-1156	40	51
69	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. *Multiple Sclerosis Journal*, **2019**, 25, 1605-1617	5	46
68	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. *Neurology*, **2014**, 82, 2158-64	6.5	44
67	Mode of action and clinical studies with alemtuzumab. *Experimental Neurology*, **2014**, 262 Pt A, 37-43	5.7	43
66	Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. *European Journal of Immunology*, **2005**, 35, 3694-703	6.1	42
65	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. *Neurology*, **2016**, 87, 1985-1992	6.5	38
64	Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. *BMJ Open*, **2018**, 8, e025333	3	37
63	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3010-3018	5.6	35
62	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 795-8	5.5	34
61	Promoting remyelination in multiple sclerosis. *Journal of Neurology*, **2021**, 268, 30-44	5.5	34
60	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. *Journal of Neurology*, **2016**, 263, 25-9	5.5	33
59	Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. *Multiple Sclerosis Journal*, **2013**, 19, 241-4	5	32
58	New treatment strategies in multiple sclerosis. *Experimental Neurology*, **2010**, 225, 34-9	5.7	31
57	Campath-1H treatment of multiple sclerosis. *Neurodegenerative Diseases*, **2008**, 5, 27-31	2.3	30
56	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. *Journal of Parkinson's Disease*, **2020**, 10, 875-891	5.3	28
55	Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. *Neurology*, **2017**, 88, 1004-1006	6.5	27
54	Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2013**, 2, 60-3	4	26
53	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. *JCI Insight*, **2017**, 2,	9.9	26

52	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. *Neurology*, **2018**, 90, 849-851	6.5	25
51	Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. *Drug Design, Development and Therapy*, **2013**, 7, 131-8	4.4	25
50	Guidelines on the use of irradiated blood components. *British Journal of Haematology*, **2020**, 191, 704-724	4.5	25
49	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**,	5.5	25
48	Hyperpolarized C MRI: A novel approach for probing cerebral metabolism in health and neurological disease. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 1137-1147	7.3	24
47	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. *Journal of Neuroimmunology*, **2014**, 271, 66-8	3.5	24
46	Alemtuzumab treatment of multiple sclerosis. *Seminars in Neurology*, **2013**, 33, 66-73	3.2	24
45	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 1273-1288	5	23
44	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. *Brain*, **2018**, 141, 786-796	11.2	23
43	Anti-IL-7 receptor monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study. *British Journal of Clinical Pharmacology*, **2019**, 85, 304-315	3.8	23
42	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. *Journal of Neurology*, **2013**, 260, 462-9	5.5	22
41	Radiologically compatible CLIPPERSmay conceal a number of pathologies. *Brain*, **2011**, 134, e187	11.2	22
40	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon 1a in MS. *Neurology*, **2016**, 87, 1464-1472	6.5	21
39	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 1779-1782	5	21
38	Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 237-43	4	17
37	Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1). *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 365-367	5.5	16
36	Monoclonal antibodies in multiple sclerosis treatment: current and future steps. *Therapeutic Advances in Neurological Disorders*, **2009**, 2, 195-203	6.6	15
35	Multiple sclerosis. *Practical Neurology*, **2009**, 9, 118-26	2.4	15

34	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. *Multiple Sclerosis and Related Disorders*, **2021**, 52, 102939	4	12
33	Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. *Therapeutic Advances in Chronic Disease*, **2013**, 4, 97-103	4.9	11
32	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. *Therapeutic Advances in Neurological Disorders*, **2021**, 14, 1756286420982134	6.6	11
31	Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.. *Multiple Sclerosis and Related Disorders*, **2021**, 57, 103458	4	10
30	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. *JCI Insight*, **2019**, 5,	9.9	10
29	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. *Contemporary Clinical Trials*, **2020**, 95, 106009	2.3	9
28	Alemtuzumab as Treatment for Multiple Sclerosis. *Cold Spring Harbor Perspectives in Medicine*, **2018** , 8,	5.4	9
27	Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. *Journal of the Neurological Sciences*, **2016**, 363, 188-94	3.2	9
26	Newer therapies for multiple sclerosis. *Annals of Indian Academy of Neurology*, **2015**, 18, S30-4	0.9	9
25	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. *Brain*, **2020**, 143, 2742-2756	11.2	8
24	Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2). *Trials*, **2019**, 20, 331	2.8	6
23	Aggressive multiple sclerosis (2): Treatment. *Multiple Sclerosis Journal*, **2020**, 1352458520924595	5	6
22	Product licences for alemtuzumab and multiple sclerosis. *Lancet, The*, **2014**, 383, 867-8	40	6
21	The outlook for alemtuzumab in multiple sclerosis. *BioDrugs*, **2013**, 27, 181-9	7.9	6
20	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. *Journal of Immunology*, **2021**,	5.3	6
19	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. *Lancet Neurology, The*, **2021**, 20, 709-720	24.1	6
18	Physician-assisted death should be available to people with MS - Commentary. *Multiple Sclerosis Journal*, **2017**, 23, 1681	5	5
17	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 295-302	5.5	5

16	Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	5
15	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. *Multiple Sclerosis Journal*, **2020**, 26, 1093-1101	5	5
14	Hypothyroid ataxia complicating monoclonal antibody therapy. *Practical Neurology*, **2017**, 17, 482-484	2.4	3
13	Alemtuzumab in Multiple Sclerosis. *Noropsikiyatri Arsivi*, **2011**, 48, 79-82	0.4	1
12	A case of anaphylaxis to alemtuzumab. *Journal of Neurology*, **2019**, 266, 780-781	5.5	1
11	A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers. *Journal of Neuroimmunology*, **2017**, 312, 4-7	3.5	1
10	Recent thymic emigrants produce antimicrobial IL-8, express complement receptors and are precursors of a tissue-homing Th8 lineage of memory cells		1
9	COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies		1
8	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. *Multiple Sclerosis Journal*, **2021**, 13524585211061335	5	1
7	Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology. *Rheumatology*, **2017**, 56, 668-670	3.9	0
6	Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution. *Journal of Neurology*, **2021**, 1	5.5	0
5	Alemtuzumab to treat multiple sclerosis393-398		
4	We are about to cure MS in the next 10 years, even though we do not know its cause: no. *Multiple Sclerosis Journal*, **2012**, 18, 784-5	5	
3	Alemtuzumab for the treatment of multiple sclerosis. *Future Neurology*, **2010**, 5, 177-188	1.5	
2	Targeting CD52 for the Treatment of Multiple Sclerosis **2013**, 385-399		
1	Campath, clones and the cause of autoimmunity. *Brain*, **2022**, 145, 1579-1580	11.2	